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patterns were assessed at 6 months following hospital discharge for patients who 
received only BMS and for patients with at least 1 DES. METHODS: A prospective, 
observational registry of 11 European countries grouped into 6 clusters recruited ACS 
patients undergoing PCI from 2008–2009. Interventional cardiologists collected data 
from ACS events up to hospital discharge, and primary care physicians and cardiolo-
gists collected 6-month data. RESULTS: Of 3042 eligible patients at baseline, 2964 
(97%) had 6-month data, of which 2842 (96%) received a stent at index PCI. The 
percentage of patients with at least 1 DES was 17% in the Czech Republic, 31% in 
Germany, 33% in Austria-Hungary, 33% in Belgium-The Netherlands, 37% in the 
Nordic countries, and 81% in Greece. The percentage of patients taking dual anti-
platelet therapy at hospital discharge ranged from 93% in Belgium-The Netherlands 
to 100% in Greece for BMS only and from 93% in Belgium-The Netherlands to 100% 
in Czech Republic for patients with DES. At 6 months, the percentage of patients 
taking dual antiplatelet therapy ranged from 45% in Czech Republic to 97% in Greece 
for BMS-only patients and from 83% in Belgium-The Netherlands to 97% in Greece 
for patients with DES. Aspirin use ranged from 89% to 100% across the countries 
and type of stent. CONCLUSIONS: Use of DES versus BMS varied among the Euro-
pean countries. In patients with BMS, there was marked variability with clopidogrel 
use at 6 months; whereas, in patients with DES, clopidogrel was used more frequently 
and with less variability.
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OBJECTIVES: Current European Society of Cardiology Guidelines recommend dual 
antiplatelet therapy for 12 months for all patients with acute coronary syndrome 
(ACS). The variations in antiplatelet treatment patterns at 6 months following hospital 
discharge were assessed in patients with unstable angina (UA), non-ST-elevation 
myocardial infarction (NSTEMI), and ST-elevation MI (STEMI) undergoing percuta-
neous intervention (PCI). METHODS: A prospective, observational registry of 11 
European countries grouped into 6 clusters recruited acute coronary syndrome (ACS) 
patients undergoing PCI from 2008–2009. Interventional cardiologists collected data 
from ACS events up to hospital discharge, and primary care physicians and cardiolo-
gists collected 6-month data. RESULTS: Of 3042 eligible patients at baseline, 2964 
patients (97%) had 6 month data; 51% of patients presented with STEMI and 49% 
with UA/NSTEMI. The median age was 62 yrs. At 6 months following hospital dis-
charge, the percentage of UA/NSTEMI and STEMI patients using clopidogrel, respec-
tively, was 70% and 40% in the Czech Republic, 84% and 89% in Germany, 98% 
and 99% in Greece, 78% and 81% in the Nordic countries, 93% and 94% in Austria 
and Hungary, and 81% and 88% in Belgium and the The Netherlands. The percentage 
of UA/NSTEMI and STEMI patients taking aspirin, respectively, was 98% and 99% 
in the Czech Republic, 89% and 90% in Germany, 97% and 100% in Greece, 95% 
and 93% in the Nordic countries, 94% and 96% in Austria and Hungary, and 91% 
and 94% in Belgium and the The Netherlands. CONCLUSIONS: Use of clopidogrel 
varied considerably between European countries at 6 months after discharge, whereas 
the majority (≥90%) of patients continued to use aspirin. Results suggest that both 
physician and patient education on continuing dual antiplatelet therapy may be 
needed.
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OBJECTIVES: This analysis aims to explore management of acute coronary syn-
dromes (ACS) from acute event to hospital discharge in Germany, and to measure 
Quality of Life (QoL) at discharge. METHODS: This 12-month international prospec-
tive, observational study recruited ACS patients undergoing percutaneous coronary 
intervention (PCI), April 2008–March 2009, capturing practice patterns, resource use 
and QoL. RESULTS: 500 ACS-PCI patients (out of the 508 recruited) were eligible: 
median age 63 yrs (IQR 53–72), median weight 82 kg (IQR 74–92), 23% female, 
24% Type II diabetics, and 27% prior myocardial infarction (MI). Index diagnosis 
was: unstable angina or non-ST-elevation MI (UA/NSTEMI)-53% and ST-elevation 
MI (STEMI)-47%. Almost all patients (96%) received stents: 68% bare metal stents 
(BMS) only, 29% drug eluting stents (DES) only and 3% both. Time from start of 
ACS symptoms to PCI was 3 days or less in 91% of UA/NSTEMI patients and 1 day 
or less in 97% of STEMI patients. Oral antiplatelet medications with loading dose 
(LD) used: aspirin-86% and clopidogrel-93%. Clopidogrel LD was administered in 
the ambulance-7%, previous hospital-8%, emergency room-32%, CCU or ICU-23%, 
catheterization lab-25%, other ward 5%. LD was administered just before or direct 
after PCI in 79% of cases. The clopidogrel LD was 600 mg in 68% and 300 mg in 
24% of cases and in-hospital maintenance dose (MD) was 75 mg in 98%. At time of 
hospital discharge, 92% of discharged patients were receiving clopidogrel (discharge 
dose 75 mg in all cases). QoL in discharged patients was good: median EQ-5D health 
state index at 0.85 (IQR 0.73–1.00). CONCLUSIONS: These real life data reﬂ ect 
treatment patterns among ACS patients managed by PCI in Germany in 2008–2009. 
Timing and place of antiplatelet loading differ between patients. The QoL of patients 
at discharge was high.
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OBJECTIVES: This study estimated market shares for six statins based on 1) the 
literature-determined lipid-lowering potential of the drugs, and 2) the distribution of 
U.S. adults depending on the amount of lipid-lowering they required. Estimated 
market shares were compared with actual market shares. METHODS: Two panels 
(1999–2000 and 2001–2002) from the National Health and Nutrition Examination 
Survey (NHANES) provided interview, demographic, and laboratory data for 3324 
people >20 years of age who were not taking a statin. In accordance with the ATP III 
Guidelines, coronary heart disease (CHD) and CHD-risk-equivalent events including 
diabetes, other risk factors such as smoking and high blood pressure, and Framingham 
scores to obtain 10-year risk estimates were identiﬁ ed and calculated, respectively for 
each person, along with percentage LDL-C lowering required to reach his or her 
LDL-C goal. Depending on the amount of lowering needed and on whether the 
individual had a liver condition, hence, enhanced risk of rhabdomyolysis, a particular 
statin or particular statins with equal probabilities were assigned to the individual; 
e.g., a person without a liver condition requiring 50% lowering of LDL-C would be 
assigned rosuvastatin or atorvastatin, each with probability = 0.5. RESULTS: Of 1643 
men surveyed, 57.88% were in the lowest-risk group (0–1 risk factors); 14.36% were 
in the highest-risk group (CHD or CHD-risk-equivalent). For the 1681 women, these 
percentages were 73.11% and 11.30%, respectively. Of people needing a statin, 
73.74% needed LDL-C lowering by <25%; only 1.16% required LDL-C lowering of 
>60%. Therapeutic market shares were estimated at 20.11% (rosuvastatin); 18.94% 
(atorvastatin); 17.89% (simvastatin); 16.96% (lovastatin); 13.05% (ﬂ uvastatin); and 
13.05% (pravastatin). CONCLUSIONS: Actual market shares are signiﬁ cantly differ-
ent from market shares based on lipid-lowering considerations. Explanations include 
direct-to-consumer advertising; varying pricing strategies; and clinical trials for addi-
tional indications and subpopulations conducted only by the market leaders.
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OBJECTIVES: By creating incentives around quality and efﬁ ciency, there exists con-
sideration to bundle hospital and physician payments around the episodes of inpatient 
surgery. We provided current payments around surgical episodes including the degree 
to which different types of providers are involved. In particular, we looked at the most 
expensive procedure performed commonly on the elderly: coronary artery bypass graft 
(CABG) surgery. METHODS: The study was based on complete national U.S. claims 
data. Managed care patients were excluded (16% in 2005) from the study because 
service provided to them was not consistently captured in the data set. We also 
excluded patients who were less than 65 years of age or over 99, and those not enrolled 
in the data set at the time of their procedures (4%). Also excluded were patients who 
were nursing home residents before surgery. Patients undergoing CABG were identi-
ﬁ ed using ICD-9 codes. Price-standardized payments from the date of admission for 
the index procedure to 30 days post-discharge were determined and categorized by 
payment type (hospital, physician, and post-acute care) and sub-type. RESULTS: The 
average total payment around an inpatient surgery episode was $45,358 for CABG. 
Hospital payments accounted for the largest of total payments (60% of the procedure), 
followed by physician payments (13%). Diagnosis-Related Group (DRG) payments 
and surgeon and anesthesia professional payments together accounted for 65% of 
total payments. Among payment types potentially leveraged by bundled payments, 
30-day readmissions accounted for 10% of total payments around surgical episodes. 
Post-acute care, including home health care and extended care facilities, accounted for 
7% of total payments. CONCLUSIONS: Payments for potentially mutable services, 
including outlier payments, 30-day readmissions, and post-acute care are considerable 
and might be reduced by incentives for hospitals and physicians to improve quality 
and efﬁ ciency.
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OBJECTIVES: Construct the disease management model for patients with Atrial 
Fibrillation (AF) in Greece, according to initial therapeutic approach. METHODS: 
The analysis was based on data from patient records of 149 geographically distributed 
cardiologists, extracted via strictly structured questionnaire-based interviews. Partici-
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pants were requested to categorize patients according to initial AF approach, i.e. 
pharmacological or non-pharmacological (interventional) treatment option. Discrete 
sets of answers were provided for each patient group. RESULTS: A pharmacological 
therapy was the initial treatment approach for 89.6% of patients (rhythm control: 
59.5%, rate control: 40.5%), whereas 5.2% had initially undergone non-pharmaco-
logical therapy, mainly catheter ablation (96% of cases). The remaining 5.2% received 
no treatment. Patients on rhythm control were mainly prescribed a Class-III (28.9%), 
Class-Ic (28.9%) or Class-II anti-arrhythmic agent, whereas 13.4% received a combi-
nation. In the rate control group, the treatments of choice were b-blockers (37.0%) 
and digoxin (24.2%). The majority of patients, also, received anti-thrombotic medica-
tion (89.0%, 91.3% and 100% for rhythm control, rate control and non-pharmaco-
logical treatment, respectively). The most frequently performed diagnostic procedures 
across groups, on an annual basis, were INR monitoring (8.3–11.5 tests/year), echo-
cardiogram (4.0–4.4), liver (1.8–2.0) and renal function tests (1.7–1.9) and Holter 
monitoring (1.4–1.6). On average 4.3, 4.0 and 3.1 consultations/year with a cardiolo-
gist are necessary for the monitoring of patients on rhythm, rate control and non-
pharmacological treatment respectively. Annual hospitalization rates for patients 
under rhythm control were 20% due to AF recurrence, 13% due to cardiovascular 
complications and 5.63% due to drug adverse reactions. For patients under rate 
control, the corresponding percentages were 6%, 6.13% and 4% and for those under 
non-pharmacological therapy 18.75%, 3% and 4.86% respectively. CONCLUSIONS: 
Pharmacological rhythm control appears to be the prevailing initial AF treatment 
option in Greece. AF management requires an intense monitoring pattern, given that 
it can lead to increased frequency of hospitalizations.
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OBJECTIVES: To assess the incidence of venous thromboembolism (VTE) and current 
practice patterns for VTE prophylaxis in hospitalised acutely ill medical patients in 
Europe. METHODS: A systematic literature search was conducted in major databases 
on the epidemiology and treatment practices of VTE prevention among adult patients 
treated in hospital for major medical conditions. Relevant studies published between 
1999 and April 2010 were captured. RESULTS: Thirty-ﬁ ve multinational and coun-
try-speciﬁ c studies were retrieved, including randomized clinical trials, registry and 
chart audits, meta-analyses, and cross-sectional, retrospective, prospective, and obser-
vational studies. Among patients admitted for an acute medical illness, the incidence 
of VTE diagnosed during hospitalization ranged from 3.01% (mean hospital stay: 4.5 
days) to 15% (day 14 from index hospitalization). While clinical guidelines recom-
mend pharmacological VTE prophylaxis to all patients hospitalised for an acute 
medical illness who are bedridden, a clear identiﬁ cation of speciﬁ c risk groups who 
would beneﬁ t from VTE prevention is lacking. In the majority of studies captured, 
prophylaxis was underused among medical inpatients (all diseases); 33% to 82% of 
all patients hospitalised for acute medical illnesses did not receive any VTE prophy-
laxis. Furthermore, among patients who did receive prophylaxis, a considerable pro-
portion received medication that was not in agreement with guidelines, due to short 
duration, suboptimal dose, or inappropriate type of prophylaxis. Of all prescriptions, 
low molecular weight heparin was the most widely prescribed anticoagulant. In most 
cases, the duration of VTE prophylaxis did not exceed hospital stay duration, and 
varied between 5 and 33.8 days (mean duration). CONCLUSIONS: VTE imposes a 
substantial burden among hospitalised medical patients. Despite the proven efﬁ cacy 
of prophylaxis, utilization remains suboptimal among medical patients at risk for 
VTE, stressing the necessity for improved or easier access to proven preventive thera-
pies among these patients. 
CARDIOVASCULAR DISORDERS – Conceptual Papers & Research on 
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OBJECTIVES: Although the 6-minute walk test (sub-maximal exercise test) histori-
cally has been used to evaluate the effect of pharmacologic intervention in adults with 
pulmonary arterial hypertension (PAH), it was not widely regarded as appropriate for 
children at all ages. Thus, Peak VO2 (maximal exercise test) was used in a pediatric 
PAH trial (A1481131) to evaluate the effect of treatment. As this is the ﬁ rst large 
controlled trial using the Peak VO2 endpoint in this population, we investigated its 
performance in terms of correlational analyses. METHODS: Relationships between 
change in Peak VO2 and other endpoints were evaluated using correlation coefﬁ cients 
and regression analyses with the data from the 16-week randomized, placebo-con-
trolled, clinical trial of sildenaﬁ l assessing Peak VO2 at both baseline and week 16 in 
106 evaluable pediatric patients. a Bland-Altman plot was used to assess the reliability 
of screen and baseline visit data. RESULTS: The intraclass correlation was 0.79 for 
the screening and baseline visit Peak VO2 data. Additionally, agreement between these 
visits was supported by a Bland-Altman plot. Correlations of percentage changes in 
Peak VO2 from baseline with the change from baseline in the Physician Global Assess-
ment (overall and for sildenaﬁ l doses) and in World Health Organization Functional 
Class (WHO FC, with baseline of I and III/IV) correlated well (correlations of ≥0.40) 
and were responsive to change, while the low correlation with the Subject Global 
Assessment (0.12) suggested inﬂ uence by factors associated with child and parental 
proxy response and instrument administration. Percentage changes in Peak VO2 gave 
no real association (0.04) with the Family Cohesion of the Child Health Question-
naire. CONCLUSIONS: In pediatric PAH, Peak VO2 measurements exhibited good 
reliability. Improvements in Peak VO2 were shown to be associated with improve-
ments in qualitative clinical endpoints, including WHO FC and physician global 
assessment.
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OBJECTIVES: In comparative effectiveness research and economic evaluations, ben-
eﬁ ts of technologies are measured using multiple outcomes measures. Information 
lacks however about the importance of these endpoints for patients. We propose a 
new methodology to integrate patient weighted outcomes in a cost-efﬁ ciency frontier. 
We illustrate this methodology by means of an efﬁ ciency frontier analysis of ﬁ ve 
alternative treatments of patients with equinovarus deformity poststroke. METHODS: 
The Analytic Hierarchy Process (AHP) is a technique for multi-criteria analysis. The 
AHP supported 140 patients to prioritize the outcome measures of treatments of 
equinovarus deformity poststroke, and 10 professionals to prioritize the treatments 
regarding the outcome measures. These outcome measures include functional out-
comes, risk and side effects, comfort, daily effort, cosmetics, and impact of the treat-
ment. Sensitivity analysis is based on bootstrapping of the participants’ priorities. 
Relative costs include the device related costs and the care related costs of the treat-
ments. RESULTS: The overall effectiveness of soft-tissue surgery (.41) is ranked ﬁ rst, 
followed by orthopedic footwear (.18), ankle-foot orthosis (.15), surface electrostimu-
lation (.14), and ﬁ nally implanted electrostimulation (.12). Implanted electrostimula-
tion (.35) and soft-tissue surgery (.34) are considered to be most expensive, followed 
by surface electrostimulation (.26), orthopedic footwear (.03) and ankle-foot orthosis 
(.02). Based on these priorities of the treatments’ overall effectiveness and costs, an 
efﬁ ciency frontier was drawn that includes decision uncertainty. CONCLUSIONS: 
The results suggest that the cost-effectiveness of implanted electrostimulation and 
surface electrostimulation are unfavourable. This new methodology for efﬁ ciency 
frontier analysis allows decision makers to integrate the outcomes about the diverse 
values and costs of health care technology, and can be applied broadly. It is particu-
larly suitable in the ﬁ eld of early technology assessment, since the AHP supports a 
systematic estimation of priors about the effectiveness of alternative treatments.
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OBJECTIVES: We used the composite quality index (CompQualTM) to examine the 
association between venous thromboembolism (VTE) events and hospital quality for 
patients who underwent major orthopedic surgery.  METHODS: Using the empirical 
Bayes approach to combine mortality rates with information on hospital volume at each 
hospital, we created an index to weight observed mortality according to how reliable it 
is estimated, with remaining weight placed on hospital volume (CompQualTM scoring 
algorithm). Then, using a national database, all patients who underwent major ortho-
pedic surgery were identiﬁ ed. Rates for patients who had a VTE event during their initial 
hospitalization were calculated. By using the algorithm, every provider in the Medicare 
data set was ranked according to their quality. Multivariate regression was used to see 
the effect of quality on VTE event rates. RESULTS: We obtained a sample that included 
2,745 patients in the VTE group. After controlling for patients’ demographic and 
clinical factors, VTE events in low quality hospitals were almost 2.5 times higher than 
VTE events in high quality hospitals (p = 0.000). We also compared the ranking with 
only volume and only for hospitals. Our combined measure to rank the hospital was 
more effective and explained more variation than the individual measures (pseudo 
R-square: 0.46 for composite score, 0.15 for volume only, 0.09 for mortality only). 
CONCLUSIONS: Using national Medicare data for patients with VTE, we found that 
a simple composite measure was a strong predictor of subsequent performance for 
operations. In this regard, it was more effective than individual measures. Such mea-
sures would be useful to help patients and payers identify low quality hospitals for 
major surgery. Any policy implementation that would decrease the variation in hos-
pital quality would have a direct effect on the rates of VTE events.
